Humacyte Clears Phase 3 Hurdle for Bioengineered Vascular Implant

The company will now conclude enrollment for the study while maintaining oversight of current participants, following the established trial protocol. This clinical milestone paves the way for a supplemental biologic license application, which Humacyte expects to submit to the Food and Drug Administration during the second half of this year. The target demographic includes adult patients facing a high risk of arteriovenous fistula maturation failure.

To support the commercial rollout of its product, branded as Symvess, and to bolster its broader research pipeline, Humacyte has launched an underwritten public offering of its common stock. While the specific volume of shares remains undisclosed, the company has granted underwriters a 30-day window to purchase an additional 15% of the offering to cover potential excess demand.